| Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, ... New England Journal of Medicine 362, 402-415, 2010 | 2870 | 2010 |
| Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis X Montalban, A Hauser, ..................... Bertolotto New England Journal Medicine, 2017 | 2105 | 2017 |
| Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The Lancet, 2012 | 1306 | 2012 |
| Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind … G Comi, V Martinelli, M Rodegher, L Moiola, O Bajenaru, A Carra, ... The Lancet, 2009 | 802 | 2009 |
| Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis MP Sormani, N De Rossi, I Schiavetti, L Carmisciano, C Cordioli, L Moiola, ... Annals of neurology 89 (4), 780-789, 2021 | 514 | 2021 |
| Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ... The Lancet, 2016 | 510 | 2016 |
| The prevalence of pain in multiple sclerosis - A multicenter cross-sectional study C Solaro, G Brichetto, MP Amato, E Cocco, B Colombo, G D'Aleo, ... Neurology, 2004 | 403 | 2004 |
| Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology BA van Rheenen W, van der Spek RAA Nat Genet. doi: 10.1038/s41588-021-00973-1. Epub 2021 Dec 6. PMID: 34873335 …, 2021 | 396* | 2021 |
| Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update M Del Campo, B Mollenhauer, A Bertolotto, S Engelborghs, H Hampel, ... Biomarkers in medicine 6 (4), 419-430, 2012 | 356 | 2012 |
| Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled … G Comi, A Pulizzi, M Rovaris, O Abramsky, T Arbizu, A Boiko, R Gold, ... The Lancet, 2008 | 356 | 2008 |
| Cognitive and psychosocial features of childhood and juvenile MS MP Amato, B Goretti, A Ghezzi, S Lori, V Zipoli, E Portaccio, L Moiola, ... Neurology, 2008 | 337 | 2008 |
| Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab PS Sørensen, A Bertolotto, G Edan, G Giovannoni, R Gold, E Havrdova, ... Multiple Sclerosis Journal 18 (2), 143-152, 2012 | 313 | 2012 |
| Guillain-Barre syndrome - A prospective, population-based incidence and outcome survey A Chio, D Cocito, M Leone, MT Giordana, G Mora, R Mutani, A Bertolotto Neurology, 2003 | 313 | 2003 |
| Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study B Khatri, F Barkhof, G Comi, HP Hartung, L Kappos, X Montalban, ... Lancet Neurology, 2011 | 300 | 2011 |
| Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica P Waters, M Reindl, A Saiz, K Schanda, F Tuller, V Kral, P Nytrova, ... Journal of Neurology, Neurosurgery & Psychiatry 87 (9), 1005-1015, 2016 | 282 | 2016 |
| Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive … F Patti, MP Amato, MP (Amato, M Trojano, M (Trojano, ... Multiple Sclerosis, 2009 | 275 | 2009 |
| Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis CH Polman, A Bertolotto, F Deisenhammer, G Giovannoni, HP Hartung, ... The Lancet Neurology 9 (7), 740-750, 2010 | 270 | 2010 |
| Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study M Rovaris, M Bozzali, G Iannucci, A Ghezzi, D Caputo, E Montanari, ... Archives of neurology 59 (9), 1406-1412, 2002 | 221 | 2002 |
| Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients A Bertolotto, F Gilli, A Sala, M Capobianco, S Malucchi, E Milano, F Melis, ... Neurology 60 (4), 634-639, 2003 | 213 | 2003 |
| In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis M Rovaris, M Bozzali, G Santuccio, A Ghezzi, D Caputo, E Montanari, ... Brain 124 (12), 2540-2549, 2001 | 212 | 2001 |
